Pathalys Pharma Stock

pathalys.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $146.75MM

Pathalys Pharma is a biopharmaceutical company with a mission to treat kidney disease with therapeutic technology. Aiming to help patients who have chronic kidney disease by meeting their unmet needs, the company created a calcimimetic drug called upacicalcet with the hopes of it being more tolerable for kidney disease patients. Patlalys Pharma was founded in 2021 by Ashwin Ram, BT Slingsby, Jay P. Shepard, Mahesh Krishnan, and Takeshi Takahashi and is headquartered in Raleigh, North Carolina.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Pathalys Pharma, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Pathalys Pharma Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Pathalys Pharma Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/20/2024 Series B $105MM $xx.xx $284.99MM Catalys Pacific, DaVita, Japan Post Investment, Jp Morgan, Kb Investment, Marshall Wace, Samsara Biocapital, Tcg Crossover Management
Price per Share
$xx.xx
Shares Outstanding
9,678,064
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
5.5%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Catalys Pacific, DaVita, Japan Post Investment, Jp Morgan, Kb Investment, Marshall Wace, Samsara Biocapital, Tcg Crossover Management
01/18/2023 Series A-1 $30MM $xx.xx $111.71MM Abingworth, Catalys Pacific, DaVita, Orbimed, The Carlyle Group
Price per Share
$xx.xx
Shares Outstanding
3,090,996
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Catalys Pacific, DaVita, Orbimed, The Carlyle Group
06/22/2021 Series A-2 $11.75MM $xx.xx $39.16MM Catalys Pacific, DaVita
Price per Share
$xx.xx
Shares Outstanding
1,513,076
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalys Pacific, DaVita

Pathalys Pharma Investors Also Invested in These Private Companies

Pathalys Pharma stock FAQs

plusminus

Can you buy Pathalys Pharma stock?

As Pathalys Pharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Pathalys Pharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Pathalys Pharma stock?

To invest in a private company like Pathalys Pharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Pathalys Pharma stock?

Yes, you may sell the Pathalys Pharma stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Pathalys Pharma stock?

If you hold private company shares of Pathalys Pharma – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Pathalys Pharma on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Pathalys Pharma a public company?

No, Pathalys Pharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Pathalys Pharma’s stock price?

Pathalys Pharma is a privately held company and therefore does not have a public stock price. However, you may access Pathalys Pharma private market stock price with Forge Data.
plusminus

What is Pathalys Pharma’s stock ticker symbol?

Pathalys Pharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Pathalys Pharma News and Media Highlights

Pathalys secures $105m to advance SHPT drug through approval

Pathalys Pharma secured $105 million in Series B financing to support clinical trials and approval efforts for its lead drug candidate upacicalcet, which treats secondary hyperparathyroidism in dialysis patients. The funding will help advance upacicalcet through Phase 3 trials and filing for FDA approval.

Pathalys Pharma Raises $105M in Series B Funding

Pathalys Pharma, a Research Triangle Park, NC-based biopharmaceutical company in the late stages of developing treatments for kidney disease, raised $105M in Series B funding. The round was led by TCGX, which was joined by other investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, and included support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.

Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDA

Pathalys Pharma raised $105 million in a series B financing to fund late-stage clinical trials and prepare regulatory submissions for upacicalcet, its kidney disease drug already approved in Japan. The oversubscribed round was led by TCGX and included several new investors. The funds will support ongoing phase 3 trials and commercial preparations for upacicalcet, which aims to treat secondary hyperparathyroidism in hemodialysis patients.

Pathalys Pharma Appoints Dr. Bastian Dehmel as Chief Medical Officer

Pathalys Pharma appointed Dr. Bastian Dehmel as Chief Medical Officer. Dehmel has over 20 years experience in biotech and pharma drug development. He will lead clinical operations and drug safety as Pathalys advances upacicalcet, a novel therapy for kidney disease, through late stage trials.
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.